Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910052 | 1.00 | HSD17B10 (0.66) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7840915 | 0.90 | ACHE (0.55) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7841104 | 0.89 | CA12 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7842227 | 0.89 | CA12 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL19479306 | 0.88 | TSHR (0.53) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7843232 | 0.88 | PPARG (0.60) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7841701 | 0.87 | CA12 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7841737 | 0.87 | ACHE (0.51) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7845468 | 0.87 | RECQL (0.58) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL24601927 | 0.87 | HSD17B10 (0.70) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023067387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-04-27 | — | — | WO | disclosed |
| EP-4159209-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | Santen Pharmaceutical Co., Ltd. (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-115515570-A | Sulfur-containing compounds useful for the treatment or prevention of presbyopia | 参天制药株式会社 | 2022-12-23 | — | — | CN | disclosed |
| US-20220151989-A1 | LIPOIC ACID PRODRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3522873-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSTOMIA | CELLIX BIO PRIVATE LTD (IN) | 2022-03-16 | — | — | EP | disclosed |
| EP-3957365-A1 | LIPOIC ACID PRODRUG | Santen Pharmaceutical Co., Ltd. (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-20150246903-A9 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | ENCORE HEALTH LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150246903-A9 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | ENCORE HEALTH LLC | 2015-09-03 | — | — | US | disclosed |
| US-20140357691-A1 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | ENCORE HEALTH LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357691-A1 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | ENCORE HEALTH LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8795706-B2 | Methods of treating ocular diseases using derivatives of lipoic acid | ENCORE HEALTH, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8795706-B2 | Methods of treating ocular diseases using derivatives of lipoic acid | ENCORE HEALTH, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2010147957-A2 | DITHIOL COMPOUNDS, DERIVATIVES, AND USES THEREFOR | ENCORE HEALTH, LLC (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100317608-A1 | Dithiol Compounds, Derivatives, and Uses Therefor | ENCORE HEALTH LLC (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317608-A1 | Dithiol Compounds, Derivatives, and Uses Therefor | ENCORE HEALTH LLC (US) | 2010-12-16 | — | — | US | disclosed |
| US-20090036516-A1 | COMPOUNDS FOR TREATING METABOLIC SYNDROME | CTG PHARMA S.R.L. (IT) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151989-A1 | LIPOIC ACID PRODRUG | ALOX15B, ALOX5, ALOX12 | HSD17B10 267/4885KMT2A 2508/4885TARDBP 2240/4885 |
| US-20090036516-A1 | COMPOUNDS FOR TREATING METABOLIC SYNDROME | GPR119, FABP4, INSR | HSD17B10 229/4885KMT2A 2571/4885TARDBP 2712/4885 |
| US-20230346744-A1 | SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA | CBS, PSEN1, PSEN2 | HSD17B10 1875/4885KMT2A 3172/4885TARDBP 1808/4885 |
| US-20140357691-A1 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | TTPA, HMGCR, CRYAB | HSD17B10 159/4885KMT2A 4128/4885TARDBP 1583/4885 |
| US-20150246903-A9 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid | TTPA, HMGCR, CRYAB | HSD17B10 159/4885KMT2A 4128/4885TARDBP 1583/4885 |
| US-20100317608-A1 | Dithiol Compounds, Derivatives, and Uses Therefor | FARS2, CRYZ, TALDO1 | HSD17B10 359/4885KMT2A 4596/4885TARDBP 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.